The Journal of Experimental Medicine · 1995 · 542 citations · 31 references
Cancer ImmunosurveillanceSynthetic Peptide AnaloguesImmunologyTumor ImmunityPathologyHer-2/neu ProtooncogeneImmunodominant PeptideImmunoeditingImmunophenotypingHla-a2.1 Anchor MotifsAntigen ProcessingSimilar EpitopeImmunotherapyMedicineCell BiologyTumor MicroenvironmentTumor BiologyOvarian Cancer
Synthetic peptide analogues of sequences in the HER-2 protooncogene (HER-2) were selected based on the presence of HLA-A2.1 anchor motifs to identify the epitopes on HER-2 recognized by ovarian tumor-reactive CTL. 19 synthetic peptides were evaluated for recognition by four HLA-A2 ovarian-specific cytotoxic T lymphocyte (CTL) lines obtained from leukocytes associated with ovarian tumors. The nonapeptide E75 (HER-2, 369-377:KIFGSLAFL) was efficient in sensitizing T2 cells for lysis by all four CTL lines. This peptide was specifically recognized by cloned CD8+ CTL isolated from one of the ovarian-specific CTL lines. E75-pulsed T2 cells inhibited lysis by the same CTL clone of both an HLA-A2+ HER-2high ovarian tumor and a HER-2high cloned ovarian tumor line transfected with HLA-A2, suggesting that this or a structurally similar epitope may be specifically recognized by these CTL on ovarian tumors. Several other HER-2 peptides were recognized preferentially by one or two CTL lines, suggesting that both common and private HER-2 epitopes may be immunogenic in patients with ovarian tumors. Since HER-2 is a self-antigen, these peptides may be useful for understanding mechanisms of tumor recognition by T cells, immunological tolerance to tumor, and structural characterization of tumor antigens.
31
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
Kirsten Falk, Olaf Rötzschke, Stefan Stevanovié et al. · Nature · 1991 · 2.4K citations · Full text
Yutaka Kawakami, S Eliyahu, Kazuyasu Sakaguchi et al. · The Journal of Experimental Medicine · 1994 · 854 citations · Full text